(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains. Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
